Artizan Biosciences Announces Multi-Year Research Collaboration with the University Medical Center Utrecht and Microviable Therapeutics SL
21 juil. 2022 07h30 HE
|
Artizan Biosciences, Inc.
NEW HAVEN, Conn., July 21, 2022 (GLOBE NEWSWIRE) -- Artizan Biosciences, Inc. (“Artizan”), a biotechnology company creating gut exclusive microbial metalloprotease inhibitors (GEMMi), a new class of...
Artizan Biosciences Announces Issuance of New U.S. Patent to Cover Proprietary Discovery Platform
29 mars 2022 07h30 HE
|
Artizan Biosciences, Inc.
NEW HAVEN, Conn., March 29, 2022 (GLOBE NEWSWIRE) -- Artizan Biosciences, Inc. (“Artizan”), a biotechnology company creating a new class of transformative precision therapeutics that target and...
Artizan Biosciences Selects Lead Product Candidate for Inflammatory Bowel Disease Therapeutic Development Program
18 janv. 2022 07h30 HE
|
Artizan Biosciences, Inc.
NEW HAVEN, Conn., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Artizan Biosciences, Inc. (“Artizan”), a precision medicine biotechnology company, today announced the selection of its lead product candidate,...
Artizan Biosciences and Biohaven Therapeutics Announce Therapeutic Development Program in Parkinson’s Disease
18 nov. 2021 07h30 HE
|
Artizan Biosciences, Inc.
NEW HAVEN, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Artizan Biosciences, Inc. (“Artizan”), a biotechnology company at the frontier of microbiome precision medicine, and Biohaven Therapeutics Ltd....
Artizan Biosciences Announces Appointment of Dr. Bridget Martell as President and Chief Executive Officer
19 oct. 2021 07h30 HE
|
Artizan Biosciences, Inc.
NEW HAVEN, Conn., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Artizan Biosciences, Inc. (“Artizan”), a biotechnology company at the frontier of microbiome precision medicine, today announced the appointment...
Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics
01 mars 2021 16h00 HE
|
Artizan Biosciences, Inc.
Agreement enables Biohaven to exercise option on up to three of Artizan’s candidates for the treatment of inflammatory bowel disease Series A-2 led by Hatteras Venture Partners and Biohaven Donnie...
Artizan Biosciences Announces Corporate Progress and Financing
10 juin 2019 07h30 HE
|
Artizan Biosciences, Inc.
Finalized Series A funding, bringing total raised to date to $12MM to support proprietary platform that enables identification of disease-driving bacteria and development of therapies for inflammatory...